| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials
|
Attili, I.
|
|
|
33 |
2 |
p. 119-122
|
artikel
|
| 2 |
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
|
Long, G.V.
|
|
|
33 |
2 |
p. 204-215
|
artikel
|
| 3 |
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
|
Soo, R.A.
|
|
|
33 |
2 |
p. 181-192
|
artikel
|
| 4 |
A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer
|
Middleton, G.
|
|
|
33 |
2 |
p. 143-157
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
33 |
2 |
p. iii
|
artikel
|
| 6 |
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
|
Niu, J.
|
|
|
33 |
2 |
p. 169-180
|
artikel
|
| 7 |
Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force
|
Özdemir, B.C.
|
|
|
33 |
2 |
p. 126-128
|
artikel
|
| 8 |
Letter to the Editor for ‘Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study’
|
Harbeck, N.
|
|
|
33 |
2 |
p. 227-228
|
artikel
|
| 9 |
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|
Popat, S.
|
|
|
33 |
2 |
p. 129-142
|
artikel
|
| 10 |
Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease
|
Remon, J.
|
|
|
33 |
2 |
p. 123-125
|
artikel
|
| 11 |
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
|
Tanizaki, J.
|
|
|
33 |
2 |
p. 216-226
|
artikel
|
| 12 |
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy
|
Kim, R.
|
|
|
33 |
2 |
p. 193-203
|
artikel
|
| 13 |
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
|
Corti, C.
|
|
|
33 |
2 |
p. 158-168
|
artikel
|
| 14 |
Table of Contents
|
|
|
|
33 |
2 |
p. i-ii
|
artikel
|
| 15 |
VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study
|
André, T.
|
|
|
33 |
2 |
p. 229-230
|
artikel
|
Tijdschrift beschrijving